US Patent Issued to TWILIGHT BIOSCIENCE on Aug. 4 for "HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use" (Maryland, Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,309, issued on Aug. 4, was assigned to TWILIGHT BIOSCIENCE INC. (Topsfield, Mass.).

"HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use" was invented by Marta Garcia Montojo (Silver Spring, Md.), Ajay Verma (Rehoboth, Mass.) and Thomas M. Lancaster (Wenham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment are described. The fusion proteins may be administered to patients having a disease or a disorder with the intention of mitigating and/or reducing the duration...